Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atezolizumab + paclitaxel + bevacizumab first-line phase II trial in advanced or metastatic triple-negative breast cancer
2019-001503-20Phase 2Completed
- Sponsor
- MEDSIR
- Start
- Jun 2020
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of atezolizumab, paclitaxel and bevacizumab in triple-negative breast cancer (TNBC) and breast cancer, sponsored by MEDSIR. Primary endpoint: Median progression-free survival. Started Jun 2020; status: completed.
02
Drugs
atezolizumabpaclitaxelbevacizumab
03
Conditions
triple-negative breast cancer (TNBC)breast cancer
Beyond the preview
Go deeper on 2019-001503-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-001503-20.